Glatiramer acetate

Xinteza Unveils Disruptive Non-Cannabaceae Source for Cannabinoid Biosynthesis in Breakthrough Research Led by Prof. Asaph Aharoni at the Weizmann Institute of Science

Retrieved on: 
Thursday, August 11, 2022
Climate change, Gene, Industry, CEO, Female, AIS, IP, Cancer, Brain, Patent, Weizmann Institute of Science, Fluid Equipment Development Company, Research, Interferon beta-1a, Enzyme, Income, Institute, Cannabinoid, Cannabis, Biosynthesis, Physics, NASDAQ, CPG, Artificial intelligence, CSE, Metabolomics, Solution, API, LinkedIn, TEL, Genetic engineering, Yeda, Fine chemical, Science, Glatiramer acetate

The company's IP portfolio is based on a license signed with Yeda, the commercial arm of the Weizmann Institute of Science.

Key Points: 
  • The company's IP portfolio is based on a license signed with Yeda, the commercial arm of the Weizmann Institute of Science.
  • Biosynthesis technologies have the potential to revolutionize cultivation-and-extraction-based production methods of cannabinoid compounds for CPG and pharma.
  • Xinteza holds an exclusive license for both cannabinoids and psychoactives from the Weizmann Institute of Science with research led by Prof. Asaph Aharoni and is diligently building an unprecedented portfolio of dozens of related IP assets and patents.
  • Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science.

Mapi Pharma to Present Late Breaking Poster Presentation on GA Depot for Treating Primary Progressive Forms of Multiple Sclerosis at CMSC 2022 Annual Meeting

Retrieved on: 
Tuesday, May 31, 2022
Diabetes, LCM, CEO, API, RMS, Remyelination, RRMS, National Harbor, Maryland, Woman, CDP, Poster, NASDAQ, Phase, EDSS, GA, NESS, CMSC, Patent, Convention center, Time, NEP, MS, Gaylord National Resort & Convention Center, Man, Multiple sclerosis, Safety, Chief executive officer, Glatiramer acetate, GLOBE, Pharmaceutical industry, PPMS, Patient, Viatris

GA Depot is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone/Glatopa).

Key Points: 
  • GA Depot is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone/Glatopa).
  • GA Depot consists of extended-release microspheres containing GA, administered intramuscularly (IM) once every 28 days.
  • Mapi Pharma partnered with Viatris (NASDAQ: VTRS) for GA Depot in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for relapsing forms of multiple sclerosis.
  • Mapi Pharma was founded by Ehud Marom who serves as Chairman & CEO of Mapi Pharma and Stem Cell Medicine.

Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda, the Commercial Arm of the Weizmann Institute of Science, for a Novel Gene Therapy Candidate for Neuronopathic Gaucher Disease and Parkinson Disease with GBA1 Mutations

Retrieved on: 
Tuesday, April 12, 2022
Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, GBA1, Patent, Lists of diseases, Weizmann Institute of Science, Cancer, Clinical trial, Yeda, Climate change, Shanghai Redtown Culture Development Co., Ltd, Interferon beta-1a, Parkinson, Yissum Research Development Company of the Hebrew University, Gaucher's disease, Research, Financial Services and Markets Authority (Belgium), CNS, Central nervous system, Brain, Program, Patient, Artificial intelligence, Parkinson's disease, MPS, AAV, CSO, Physics, Company, Forward-looking statement, GM1, LYS, Income, Business development, Fragile X syndrome, Autism, Business, Adaptive clinical trial, PD, Pharmaceutical industry, Gaucher, Glatiramer acetate

Since 2020, Lysogene has been collaborating with Prof. Anthony Futerman at the Weizmann Institute of Science with the aim of developing a novel AAV gene therapy approach for neuronopathic Gaucher disease, Parkinson disease, and other diseases associated with mutations of the GBA1 gene.

Key Points: 
  • Since 2020, Lysogene has been collaborating with Prof. Anthony Futerman at the Weizmann Institute of Science with the aim of developing a novel AAV gene therapy approach for neuronopathic Gaucher disease, Parkinson disease, and other diseases associated with mutations of the GBA1 gene.
  • Under the terms of the agreement, Lysogene will be responsible for the preclinical and clinical development, manufacturing, regulatory activities, and commercialization of the drug candidate, globally.
  • We continue to replenish our early-stage pipeline to position Lysogene as a key player in the field of gene therapy translational science.
  • Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS).

Mapi Pharma to Present Posters on GA Depot for Treating Relapsing Forms of Multiple Sclerosis (MS) and Primary Progressive Forms of Multiple Sclerosis at the American Academy of Neurology (AAN) 2022 Annual Meeting

Retrieved on: 
Thursday, March 31, 2022
Multiple sclerosis, Safety, NASDAQ, Patent, API, American Academy of Neurology, Remyelination, SPMS, NESS, GA, CEO, Poster, Chief executive officer, Glatiramer acetate, LCM, Diabetes, MS, Time, GLOBE, American Academy, RMS, AAN, Patient, IP, Antibody, Pharmaceutical industry, Lithium, Viatris, PPMS, RRMS

GA Depot is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone/Glatopa).

Key Points: 
  • GA Depot is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone/Glatopa).
  • At AAN, we will be presenting 5 year follow up data from our successful Phase IIa study in RRMS.
  • Mapi Pharma partnered with Viatris (NASDAQ: VTRS) for GA Depot in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for relapsing forms of multiple sclerosis.
  • Mapi Pharma was founded by Ehud Marom who serves as Chairman & CEO of Mapi Pharma and Stem Cell Medicine.

Mapi Pharma Receives U.S. Patent Covering Methods of Suppressing or Alleviating Primary or Secondary Progressive Multiple Sclerosis with a Sustained Release Glatiramer Acetate Depot

Retrieved on: 
Wednesday, March 30, 2022
Multiple sclerosis, NASDAQ, Patent, API, American Academy of Neurology, PPMS, 1836 U.S. Patent Office fire, Phase, SPMS, NESS, GA, CEO, Chief executive officer, LCM, Safety, Diabetes, MS, GLOBE, RMS, American Academy, Glatiramer acetate, RRMS, IP, Pharmaceutical industry, Viatris

11,167,003 entitled: Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems.

Key Points: 
  • 11,167,003 entitled: Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems.
  • GA Depot is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone/Glatopa), designed to be administered as an intramuscular injection once every four weeks.
  • GA Depot is also currently being evaluated in a multinational Phase II for primary progressive multiple sclerosis (PPMS).
  • Mapi Pharma was founded by Ehud Marom who serves as Chairman & CEO of Mapi Pharma and Stem Cell Medicine.

COPAXONE® Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis

Retrieved on: 
Thursday, February 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Private Securities Litigation Reform Act, Pain, Growth, Woman, Safety, Master of Science, NYSE, MS, RMS, All European Academies, Pregnancy, Glatiramer acetate, Neurology, Department, TEVA, Intention-to-treat analysis, Teva Pharmaceuticals, DOI, EAN, Research, Multiple sclerosis, Frequency, Teva, Failure, MD, TASE, Mother, Medication package insert, Incidence, Pregnancy rate, Chest pain, Patient, Review, Epidemiology, Doctor of Science, Travel, Flushing, BA, COVID-19, Department of Neurology, Xuanwu hospital, Itch, Rash, Investment, Annual report, Human, HIV disease progression rates, GA, Diagnosis, Compliance, MS1, Congress, COBRA, Swelling, Forward-looking statement, Medical device, Birth control, Pharmaceutical industry, EU, the COBRA Study, COPAXONE®, COPAXONE®, Teva, THE COBRA STUDY, COPAXONE®, COPAXONE®, TEVA

The COPAXONE label change provides breastfeeding patients with MS the choice to breastfeed while on MS treatment.

Key Points: 
  • The COPAXONE label change provides breastfeeding patients with MS the choice to breastfeed while on MS treatment.
  • Real-world safety of COPAXONE in Offspring of Breastfeeding and Treated Relapsing Multiple Sclerosis (RMS) patients (COBRA study) was retrospective data analysis using the national German Multiple Sclerosis and Pregnancy Registry.
  • COPAXONE (Glatiramer Acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
  • New Safety Data on treatment with COPAXONE (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis: COBRA study presented at the 7th Congress of the European Academy of Neurology (EAN).

Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders

Retrieved on: 
Tuesday, January 25, 2022
Interferon beta-1a, E3, United States Air Force Scientific Advisory Board, Physics, Queen, Research, Weizmann, Weizmann Institute of Science, Â, Climate change, Brain, MGD, Technology, Artificial intelligence, NASDAQ, Therapy, Cancer, Protein, Patient, Yissum Research Development Company of the Hebrew University, Proteomics, GLOBE, Income, Yeda, Patent, Pharmaceutical industry, Fine chemical, Glatiramer acetate, Shepherdswell with Coldred

Dr. London and his team at the Weizmann Institute developed CoLDR technology, which uses covalent chemical inhibitors as a targeting system for selective cargo release (e.g.

Key Points: 
  • Dr. London and his team at the Weizmann Institute developed CoLDR technology, which uses covalent chemical inhibitors as a targeting system for selective cargo release (e.g.
  • This technology has the potential to be applied to the targeted protein degradation field, including the development of novel molecular glue degraders for cancer and other diseases.
  • Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader medicines.
  • Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science.

New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

Retrieved on: 
Wednesday, October 13, 2021
Health, Nobel Prize, IM, Biotechnology, DMT, DMTS, Neurodegeneration, Ozanimod, Research, News, Vaccination, Immunoglobulin G, Congress, Nasdaq, Intellectual property, European Committee on Radiation Risk, Neuropathic pain, COVID-19, MS, Neuromuscular Disorders, Sphingosine-1-phosphate, U.S. Securities and Exchange Commission, Multiple sclerosis, RNA transfection, Natalizumab, Disease, Organic acid, Risk, Biogen, Dementia, Cleveland Clinic, BIIB, Failure, Rituximab, Neuropsychiatry, Interferon, Safety, 2021 Essex County Council election, Alemtuzumab, Ophthalmology, Drug development, IFN, Treatment, Private Securities Litigation Reform Act, Siponimod, GLOBE, MRI, Technology, S1P, Randomness, Spinal muscular atrophy, Partner, Glatiramer acetate, Movement disorders, Pharmaceutical industry, Frankincense

Using data from the MS PATHS network in the U.S., Germany and Spain, researchers evaluated blood samples from 322 participants 28-90 days after their last COVID-19 vaccine dose.

Key Points: 
  • Using data from the MS PATHS network in the U.S., Germany and Spain, researchers evaluated blood samples from 322 participants 28-90 days after their last COVID-19 vaccine dose.
  • Preliminary results suggest that anti-CD20 and sphingosine 1-phosphate (S1P) therapies may reduce the antibody response to COVID-19 vaccination.
  • These insights are important in helping providers and patients alike manage MS while seeking to protect patients from COVID-19 through vaccination.
  • Leveraging the unique MS PATHS network, we were able to quickly generate data on the impact of the different MS DMTs on COVID-19 vaccine antibody responses.

New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis

Retrieved on: 
Wednesday, October 13, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Meta-analysis, Teva, Flushing, Mother, DMT, DMTS, Itch, Management of multiple sclerosis, EAN, NYSE, Patient, Incidence, Hospital, RMS, COVID-19, MS, Physician, GA, Growth, Child, Human, Multiple sclerosis, Woman, Rash, Teva Pharmaceuticals, TEVA, TASE, Disease, Travel, Pain, Failure, Chest pain, Annual report, Investment, Intention-to-treat analysis, Frequency, Private Securities Litigation Reform Act, Forward-looking statement, Live birth, Data, Pregnancy, Thought, Breastfeeding, Compliance, COBRA, Glatiramer acetate, Swelling, Birth control, Frankincense, Pharmaceutical industry, the Study, COPAXONE®, Teva, THE STUDY, COPAXONE®, TEVA

There is historically limited clinical safety data for infants who are breastfed by mothers undergoing treatment for MS including during the pregnancy period.

Key Points: 
  • There is historically limited clinical safety data for infants who are breastfed by mothers undergoing treatment for MS including during the pregnancy period.
  • Patients were eligible for the study if they were diagnosed with relapsing MS (RMS), gave a live birth, were breastfeeding under GA treatment (COPAXONE 20 or 40 mg/mL) or breastfeeding under no DMT treatment.
  • Al, Safety analysis of offspring breastfed by mothers on glatiramer acetate therapy for relapsing multiple sclerosis; presented at EAN 2021.
  • Real-world safety of Copaxone in Offspring of Breastfeeding and Treated Relapsing Multiple Sclerosis (RMS) pAtients (COBRA study) is a retrospective data analysis using data of the German Multiple Sclerosis and Pregnancy Registry.

Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Sclerosis (MS) at ECTRIMS 2021

Retrieved on: 
Monday, October 11, 2021
PPMS, Ezra Ichilov, NESS, NCE, Remyelination, RMS, New chemical entity, MS, The X Factor Digital Experience, GLOBE, GA, Exosome, Safety, IIA, Tel Aviv Sourasky Medical Center, Glatiramer acetate, Multiple sclerosis, Viatris, Patient, RRMS, Medical device, Pharmaceutical industry

NESS ZIONA, Israel, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative solutions for neurological indications, announced today that the company will present recent advancements from its pipeline for treating MS at the leading MS conference, ECTRIMS 2021 Digital Experience, to be held virtually, October 13-15, 2021. Mapi was selected to present pre-clinical and clinical results on breakthrough advancements in two of its development programs.

Key Points: 
  • Mapi was selected to present pre-clinical and clinical results on breakthrough advancements in two of its development programs.
  • In addition, Mapi plans to initiate clinical studies for the treatment of MS patients using the companys novel anti-BMP treatment for remyelination.
  • The product is based on an invention by Dr. Arnon Karni, of the Tel Aviv Sourasky Medical Center (Ichilov), Israel.
  • The company welcomes attendees to meet with us virtually at ECTRIMS 2021 to learn more about:
    PPMS: Glatiramer acetate depot (extended-release) phase IIa study in patients with primary progressive multiple sclerosis: safety and efficacy snapshot